Disease Slowing in PD: How Will We Know It When We See It?
(Thursday, December 10, 2009 7:00 PM - 8:00 PM ET)

Description and Intended Audience:

This segment features Dr. Karl Kieburtz focusing on Early Diagnosis and Treatment of Parkinson's Disease. This activity is intended for neurologists, pharmacists, and other medical professionals with a specific interest in the management of Parkinson's disease.

Learning Objectives:

Upon completion of this Teleconference, participants should be able to:

Identify the main methods used to identify drugs that may slow PD progression
Discuss the results of recent clinical trials assessing drugs to slow PD progression
Describe the difference between a drug improving PD features in the short term, and a drug changing the long-term cause of PD

Speaker Information and Disclosures:

Karl Kieburtz, MD
Professor, Department of Neurology
University of Rochester Medical Center
Director, Center for Human Experimental Therapeutics, Rochester, NY

Karl Kieburtz, MD, is Professor of Neurology, Community & Preventive Medicine, Environmental Medicine and the Director of the Center for Human Experimental Therapeutics. He is helping to develop a T1 Key Function for the CTSI. His primary clinical and research interests are neurodegenerative diseases affecting the basal ganglia, particularly Parkinson disease, Huntington disease, and HIV related neurologic disorders. He is the principal investigator for the NINDS sponsored trials of neuroprotective agents for PD (NET-PD) and currently chairs the Executive Committee of the Parkinson Study Group. He also directs the Coordination Center for other NIH and foundation supported multi-center academic research consortia.

Disclosure: Dr. Karl Kieburtz discloses research grant support from: National Institutes of Health (NEI, NINDS, NIA), the Michael J Fox Foundation, Medivation, Neurosearch, and Pfizer.
He is also serving as a consultant to:
The United States Food and Drug Administration and National Institutes of Health (NINDS), Abbott, Biogen Idec, Ceregene, EMD Serono, FoldRx, Impax, Ipsen, Lilly, Lundbeck, Merz , Neurosearch, Novartis, Orion, Prestwick, Schering-Plough, Solvay, Teva, UCB Pharma, and providing legal consulting to Pfizer and the Welding Rod Litigation Defendants

CE Information:

Physicians:

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Cine-Med and Astute Technology. Cine-Med is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Cine-Med, Inc. designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists:

Cine-Med is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is accredited for 0.1 CEU (1.0 contact hour) of continuing education credit. ACPE Universal Number 0399-9999-09-027-H01-P. Activity type: knowledge-based.

How to get CE credit:

To receive credit, participants must view the webcast, register on this site, and successfully complete the post-test and evaluation (successful passing grade >=70%). Certificates can be printed on line.